Search - tctmd.com

Displaying 441 - 460 of 1179

Sort: Relevancy | Date

Presentation Intravascular Coronary Imaging and Physiology 2018

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

Presenter: Rasha Al-Lamee

May 05, 2018

Podcast TCTMD Talking Points

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

May 02, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

News Conference News SCAI 2018

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Todd Neale

April 27, 2018

News Daily News

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

Todd Neale

April 24, 2018

Podcast TCTMD Talking Points

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock

April 18, 2018

News Daily News

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Michael O'Riordan

April 05, 2018

News Daily News

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Yael L. Maxwell

April 04, 2018

Podcast TCTMD Talking Points

Robotic PCI in Practice and Training

April 04, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

Presentation CIT 2018

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

Presenter: Ran Kornowski

March 23, 2018

Podcast TCTMD Talking Points

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque

March 21, 2018

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

News Conference News ACC 2018

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

Yael L. Maxwell

March 12, 2018

Presentation ACC 2018

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

Presenter: Sony Tuteja

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Conference News ACC 2018

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

Yael L. Maxwell

March 11, 2018

News Conference News ACC 2018

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

Shelley Wood

March 11, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

Advertisement

PCI should not be first line therapy for patients with stable CAD – Lessons learned from ORBITA

ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI

Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib

CULPRIT-SHOCK: A Randomized Trial of Multivessel PCI in Cardiogenic Shock

Rates of Heart Failure After Acute MI Declining, Statewide Analysis Shows

Another Observational Study Supports Role for Genotype-Guided Antiplatelet Choices Post-PCI

Robotic PCI in Practice and Training

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Optimal Pharmacology and PCI Strategy in STEMI & Multivessel Disease

VAMPIRE 3: A Randomized Trial of Distal Filter Protection During PCI of High-Risk Plaque

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial

A Pragmatic Randomized Trial of CYP2C19 Genotyping Implementation Following Percutaneous Coronary Intervention (PCI)

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Genetic Testing Influences Post-PCI Antiplatelet Prescriptions, but Other Factors Also Play a Role

ACC 2018, Day Two: Antiplatelets in ACS, Dabigatran in Noncardiac Surgery, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content